Find a Clinical Trial
The clinical trials at Gundersen offer the same cutting-edge treatments as those at other top medical research hospitals – and often much sooner than they’re available to everyone.
Showing 10 of 86 trials
NCI-2020-03472
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Adult (18-64)
Older adult (65+)
NCI-2022-10845
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Child (birth - 17)
Adult (18-64)
NCI-2021-02851
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Adult (18-64)
Older adult (65+)
CCTG MA.39
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Adult (18-64)
Older adult (65+)
NRG-HN009
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
Adult (18-64)
Older adult (65+)
NRG-BN011
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Adult (18-64)
Older adult (65+)
NCI-2022-06842
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Child (birth - 17)
Adult (18-64)
Older adult (65+)
NCI-2020-06838
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
Adult (18-64)
Older adult (65+)
NCI-2020-00752
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Adult (18-64)
Older adult (65+)
S1800E
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Adult (18-64)
Older adult (65+)